Literature DB >> 15464662

Metabolic storage diseases: amyloidosis.

Elizabeth M Brunt1, Dina G Tiniakos.   

Abstract

This article provides an overview of the current concepts in pathogenesis, epidemiology, clinical significance, and treatment options for amyloidosis. Emphasis is given to hepatic amyloidosis, which ranges from a clinically insignificant histologic curiosity to a harbinger of widespread disease accompanied by a poor prognosis. Clinical characteristics and clues to the diagnosis are discussed as well as the importance of histologic confirmation and the controversy surrounding liver biopsy.

Entities:  

Mesh:

Year:  2004        PMID: 15464662     DOI: 10.1016/j.cld.2004.06.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  A case of hepatomegaly.

Authors:  D Joshi; A Belgaumkar; V Ratnayake; A Quaglia; D Austin
Journal:  Postgrad Med J       Date:  2007-10       Impact factor: 2.401

2.  [Amyloidosis in liver biopsies].

Authors:  Z Gioeva; B Kieninger; C Röcken
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

3.  Renal AA Amyloidosis in Patients with Type 2 Diabetes Mellitus.

Authors:  Ramón Díez; Magdalena Madero; Gerardo Gamba; Juan Soriano; Virgilia Soto
Journal:  Nephron Extra       Date:  2014-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.